Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.77 |
| ▸ | FLT1 | P17948 | 11/20 | 0.77 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.77 |
| ▸ | EGFR | P00533 | 10/20 | 0.68 |
| ▸ | RET | P07949 | 3/20 | 0.66 |
| ▸ | KIF5B | P33176 | 2/20 | 0.66 |
| ▸ | FLT4 | P35916 | 6/20 | 0.64 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19220777 | 0.91 | RET (0.67) | KDRFLT1FGFR1EGFRRET | |
| SCHEMBL17520351 | 0.91 | KDR (0.78) | KDRFLT1FGFR1EGFRRET | |
| SCHEMBL19006646 | 0.90 | EGFR (0.66) | KDRFLT1FGFR1EGFRRET | |
| SCHEMBL17520325 | 0.89 | KDR (0.77) | KDRFLT1FGFR1EGFRRET | |
| SCHEMBL19220775 | 0.89 | RET (0.64) | KDRFLT1FGFR1EGFRRET | |
| SCHEMBL8789 | 0.83 | EGFR (0.84) | KDREGFRRETKIF5BFLT4 | |
| SCHEMBL19006946 | 0.82 | EGFR (0.81) | KDREGFRRETKIF5BFLT4 | |
| SCHEMBL11517 | 0.81 | KDR (0.84) | KDRFLT1FGFR1EGFRRET | |
| SCHEMBL1887966 | 0.81 | KDR (0.71) | KDRFLT1FGFR1EGFRRET | |
| SCHEMBL2102985 | 0.81 | EGFR (1.00) | KDREGFRFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | claimed |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2016-10-20 | — | — | US | disclosed |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20130005726-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2013-01-03 | — | — | US | disclosed |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | SLIWKOWSKI MARK X (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120189573-A1 | Methods of using death receptor agonists and EGFR inhibitors | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8163287-B2 | Combination therapy of her expressing tumors | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | US | disclosed |
| US-20110262436-A1 | TREATMENT METHOD | GENENTECH, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2007013950-A9 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH INC (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007013950-A2 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2006089015-A2 | METHODS OF USING DEATH RECEPTOR AGONISTS AND EGFR INHIBITORS | GENENTECH, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | GENENTECH, INC. | 2006-08-24 | — | — | US | disclosed |
| WO-2005048928-A2 | METHODS FOR TREATING VIRAL INFECTION | GEORGE MASON INTELLECTUAL PROPERTY (US) | 2005-06-02 | — | — | WO | disclosed |
| EP-0823900-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-12-27 | — | — | EP | disclosed |
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |
| EP-0823900-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996033980-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120189573-A1 | Methods of using death receptor agonists and EGFR inhibitors | EGFR, ERBB4, TNFRSF9 | KDR 50/4885FLT1 253/4885FGFR1 1140/4885 |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | KDR 34/4885FLT1 46/4885FGFR1 47/4885 |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | EGFR, ERBB4, TNFRSF9 | KDR 50/4885FLT1 253/4885FGFR1 1140/4885 |
| US-20070020261-A1 | Combination therapy of her expressing tumors | ERBB2, EGFR, ERBB3 | KDR 34/4885FLT1 46/4885FGFR1 47/4885 |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | KDR 33/4885FLT1 18/4885FGFR1 19/4885 |
| US-20110262436-A1 | TREATMENT METHOD | HGF, HDGF, FGF2 | KDR 424/4885FLT1 86/4885FGFR1 14/4885 |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | KDR 33/4885FLT1 18/4885FGFR1 19/4885 |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | KDR 395/4885FLT1 305/4885FGFR1 462/4885 |
| US-20130005726-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | NOD2, RIPK2, RIPK1 | KDR 3236/4885FLT1 2997/4885FGFR1 2253/4885 |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | KDR 34/4885FLT1 46/4885FGFR1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.